ICU Medical ( (ICUI) ) has released its Q3 earnings. Here is a breakdown of the information ICU Medical presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ICU Medical, Inc. is a global leader in the development and sale of infusion systems, consumables, and critical care products, catering to hospital and home care settings. Headquartered in San Clemente, California, the company is known for its focus on quality and innovation in the medical products sector.
In its third quarter of 2025 earnings report, ICU Medical reported a revenue of $537 million, a decrease from the previous year’s $589.1 million. Despite the drop in revenue, the company improved its gross margin to 37% from 35% and reduced its net loss significantly from $33 million in the previous year to $3.4 million.
Key financial highlights include an increase in adjusted diluted earnings per share to $2.03 from $1.59 and a rise in adjusted EBITDA to $105.9 million from $94.8 million. The company also saw growth in its Consumables and Infusion Systems product lines, although its Vital Care line experienced a decline due to the disposal of its IV Solutions business.
Looking ahead, ICU Medical has updated its fiscal year 2025 guidance, projecting a reduced GAAP net loss range and increased adjusted EBITDA and earnings per share estimates. The company remains optimistic about its financial trajectory, reflecting confidence in its strategic initiatives and market position.